Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,068.01
(
-0.58%
)
US TECH 100
25,759.20
(
-0.43%
)
Dow Jones
49,219.32
(
-0.46%
)
Brent Oil
94.72
(
4.46%
)
Bitcoin
75,553.92
(
-0.45%
)
News Focus
News Focus
Post# of 3681
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

north40000

Send PM Follow Ignore
Followers 269
Posts 18896
Boards Moderated 0
Alias Born 01/19/2006

north40000

Member Level

Re: None

Monday, 01/11/2016 10:25:14 AM

Monday, January 11, 2016 10:25:14 AM

Post# of 3681
On January 8, 2016, Novartis notified GenVec that it was pausing enrollment in the clinical trial of CGF166 to conduct a safety review of patient data, based on the recommendation of the trial’s data safety monitoring board. The trial will continue to collect new safety and efficacy data on patients currently enrolled in the study.

http://ih.advfn.com/p.php?pid=nmona&article=69954546
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today